Launched in Lausanne in 2019, Nuvamid is a clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases.
Nuvamid’s Swiss team has developped a unique expertise with endogenous molecules to offer breakthrough therapeutics for the treatment of rare blood diseases.
In cooperation with leading partners and institutions in Switzerland (Lausanne University), France (EFS, INSERM, CNRS), and the USA (Buck Institute), Nuvamid has aquired a unique knowledge in blood cells disorders. Our lead molecule NUV01, is currently evaluated in three Phase 2 trials.
Nuvamid’s research is built upon the emerging scientific findings linking age-related disease pathologies with NAD metabolism.
Nuvamid designed novel NAD metabolism modulators and gathered extensive preclinical data to develop a portfolio of drugs targeting immune disorders.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Avenue Reverdil 4-6, Nyon,vaud 1260,switzerland
- Industry
- Biotechnology
- Website
- nuvamid.com
- Keywords
- NEW YORK.
- HQ
- Nyon, Vaud
Nuvamid Questions
Nuvamid's website is nuvamid.com
Nuvamid's LinkedIn profile is https://ch.linkedin.com/company/nuvamid
Nuvamid has
4 employees.
View email and phone details for 4
employees at Nuvamid.
Nuvamid's industry is
Biotechnology
Nuvamid's top competitors are
Lys Therapeutics,
Seneque,
Cansino Biologics Inc.康希诺生物,
Elevant,
Ibex Therapeutics,
Limula,
Anemos Therapeutics,
Lgd France,
Univercells,
The Global Centre For Risk And Innovation (Gcri).
Nuvamid's categories are Biotechnology
Nuvamid's founding year is 2019
